Insulin
Insulin is only given parenterally (subcutaneous or IV) Various preparations have different durations of action 
 

Mechanism

bind transmembrane insulin receptor
activate tyrosine kinase
phosphorylate specific substrates in each tissue type
liver
↑ glycogenesis
store glucose as glycogen
muscle
↑ glycogen and protein synthesis
↑ K+ uptake 
fat
increase triglyceride storage

Clinical use

type I DM
type II DM
life-threatening hyperkalemia
increases intracellular K+
stress-induced hyperglycemia
 

Toxicity
hypoglycemia
hypersensitivity reaction (very rare)

Insulin Synthesis
first generated as preproinsulin with an A chain and B chain connected by a C peptide. 
c-peptide is cleaved from proinsulin after packaging into vesicles leaving behind the A and B chains

Estimation of the risk of anesthesia (American Society of Anesthesiologists scale)

• ASA 1: healthy patient.

• ASA 2: patient with stable, treated illness like arterial hypertension, diabetes melitus, asthma bronchiale, obesity

• ASA 3: patient with systemic illness decreasing sufficiency like heart illness, late infarct

• ASA 4: patient with serious illness influencing his state like renal insuficiency, unstable hypertension, circulatory insuficiency

• ASA 5: patient in life treatening illness

• ASA 6: brain death- potential organ donor

Operator position

For the right-handed operator, the 8 and 10 o’clock position and for left-handed operators, the corresponding 2 and 4 o’clock position almost always allows for optimal visualization of the injection field.

On the basis of Receptors, drugs can be divided into four groups,

a. agonists

b. antagonists

c. agonist-antagonists

d. partial agonists

a. Agonist

morphine fentanyl pethidine

Action : activation of all receptor subclasses, though, with different affinities

b. Antagonist

Naloxone , Naltrexone

Action :  Devoid of activity at all receptor classes  

c. Partial Agonist: (Mixed Narcotic Agonists/Antagonists)

Pentazocine, Nalbuphine, Butorphanol , Buprenorphine

Action: activity at one or more, but not all receptor types

With regard to partial agonists, receptor theory states that drugs have two independent properties at receptor sites,

a. affinity

The ability, or avidity to bind to the receptor
Proportional to the association rate constant, Ka

b. efficacy

or, intrinsic activity, and is the ability of the D-R complex to initiate a pharmacological effect

Drugs that produce a less than maximal response and, therefore, have a low intrinsic activity are called partial agonists.

These drugs display certain pharmacological features,

a. the slope of the dose-response curve is less than that of a full agonist

b. the dose response curve exhibits a ceiling with the maximal response below that obtainable by a full agonist

c. partial agonists are able to antagonise the effects of large doses of full agonists

Nalidixic acid:

Nalidixic acid is the basis for quinolone antibiotics. It acts bacteriostatically (that is, it inhibits growth and reproduction) or bactericidally (it kills them) on both Gram positive and Gram negative bacteria, depending on the concentration. It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, Enterobacter and Klebsiella.

Gentamicin

Gentamicin is a aminoglycoside antibiotic, and can treat many different types of bacterial infections, particularly Gram-negative infection.

Gentamicin works by binding to a site on the bacterial ribosome, causing the genetic code to be misread.

Like all aminoglycosides, gentamicin does not pass the gastro-intestinal tract, so it can only be given intravenously or intramuscularly.

Gentamicin can cause deafness or a loss of equilibrioception in genetically susceptible individuals. These individuals have a normally harmless mutation in their DNA, that allows the gentamicin to affect their cells. The cells of the ear are particularly sensitive to this.

Gentamicin can also be highly nephrotoxic, particularly if multiple doses accumulate over a course of treatment. For this reason gentamicin is usually dosed by body weight. Various formulae exist for calculating gentamicin dosage. Also serum levels of gentamicin are monitored during treatment.

E. Coli has shown some resistance to Gentamicin, despite being gram-negative